Neville Rodie & Shaw Inc. Sells 6,470 Shares of Zoetis Inc. $ZTS

Key Points

• Neville Rodie & Shaw Inc. reduced its holdings in Zoetis Inc. by 5.3%, selling 6,470 shares during the second quarter, leaving them with 116,283 shares worth $18.13 million.
• Several institutional investors, including Vanguard Group Inc. and Polen Capital Management LLC, have increased their stakes in Zoetis, reflecting strong institutional interest in the company.
• Zoetis reported quarterly earnings of $1.76 per share, exceeding analyst estimates and representing a year-over-year revenue increase of 4.2% to $2.46 billion.

Neville Rodie & Shaw Inc. decreased its holdings in Zoetis Inc. (NYSE:ZTS - Free Report) by 5.3% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 116,283 shares of the company's stock after selling 6,470 shares during the period. Zoetis comprises about 1.3% of Neville Rodie & Shaw Inc.'s investment portfolio, making the stock its 20th biggest holding. Neville Rodie & Shaw Inc.'s holdings in Zoetis were worth $18,134,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of the business. Vanguard Group Inc. increased its holdings in shares of Zoetis by 0.5% in the 1st quarter. Vanguard Group Inc. now owns 41,556,164 shares of the company's stock worth $6,842,222,000 after purchasing an additional 189,287 shares in the last quarter. Polen Capital Management LLC increased its holdings in shares of Zoetis by 17.6% in the 1st quarter. Polen Capital Management LLC now owns 8,796,847 shares of the company's stock worth $1,448,401,000 after purchasing an additional 1,313,653 shares in the last quarter. Northern Trust Corp increased its holdings in shares of Zoetis by 1.2% in the 1st quarter. Northern Trust Corp now owns 6,504,902 shares of the company's stock worth $1,071,032,000 after purchasing an additional 78,508 shares in the last quarter. Goldman Sachs Group Inc. increased its holdings in shares of Zoetis by 2.2% in the 1st quarter. Goldman Sachs Group Inc. now owns 5,146,024 shares of the company's stock worth $847,293,000 after purchasing an additional 109,791 shares in the last quarter. Finally, Brown Advisory Inc. increased its holdings in shares of Zoetis by 7.6% in the 1st quarter. Brown Advisory Inc. now owns 4,408,542 shares of the company's stock worth $725,866,000 after purchasing an additional 312,746 shares in the last quarter. Institutional investors own 92.80% of the company's stock.

Zoetis Stock Performance

NYSE:ZTS opened at $148.33 on Friday. The stock has a 50-day simple moving average of $152.32 and a two-hundred day simple moving average of $157.31. Zoetis Inc. has a 52-week low of $139.70 and a 52-week high of $200.33. The company has a debt-to-equity ratio of 1.05, a quick ratio of 1.04 and a current ratio of 1.76. The firm has a market capitalization of $65.74 billion, a PE ratio of 25.53, a P/E/G ratio of 2.42 and a beta of 0.89.

Zoetis (NYSE:ZTS - Get Free Report) last released its quarterly earnings results on Tuesday, August 5th. The company reported $1.76 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.62 by $0.14. Zoetis had a return on equity of 56.90% and a net margin of 27.83%.The business had revenue of $2.46 billion during the quarter, compared to analyst estimates of $2.41 billion. During the same quarter in the previous year, the company posted $1.56 earnings per share. Zoetis's revenue for the quarter was up 4.2% on a year-over-year basis. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. Analysts forecast that Zoetis Inc. will post 6.07 EPS for the current year.

Analyst Upgrades and Downgrades

Several analysts recently commented on the company. Leerink Partners lowered Zoetis from an "outperform" rating to a "market perform" rating and cut their price objective for the stock from $180.00 to $155.00 in a report on Thursday, July 17th. Leerink Partnrs lowered Zoetis from a "strong-buy" rating to a "hold" rating in a report on Thursday, July 17th. Piper Sandler lifted their price objective on Zoetis from $210.00 to $215.00 and gave the stock an "overweight" rating in a report on Monday, August 11th. Stifel Nicolaus lowered Zoetis from a "buy" rating to a "hold" rating and cut their price objective for the stock from $165.00 to $160.00 in a report on Wednesday, June 18th. Finally, Argus reaffirmed a "buy" rating and issued a $190.00 price objective on shares of Zoetis in a report on Tuesday. Five equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $200.88.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.